Monday, February 13, 2023

8:00PM – 9:00PM ET

Please note this Clinical Conversation program is 8:00PM Eastern, 7:00PM Central, 6:00PM Mountain and 5:00PM Pacific.

Presenting Faculty:

Judy E. Kim, MD
Professor of Ophthalmology and Visual Sciences
Professor at the Graduate School of Biomedical Sciences
Director of Teleophthalmology and Research
Medical College of Wisconsin
Milwaukee, WI

Charles Vega, MD, FAAFP
Health Sciences Clinical Professor
Department of Family Medicine
Assistant Dean for Culture and Community Education
UC Irvine School of Medicine
Irvine, California

PROGRAM OVERVIEW

This virtually live clinical conversation exchange educational series focuses on timely screening and identification of diabetic retinopathy (DR) and/or diabetic macular edema (DME) and the impact that timely treatment as well as team-based approaches can have on vision.  Engage with expert discussion from both ophthalmology and primary care perspectives to learn more about the benefits of early detection and intervention, the role of vascular endothelial growth factor (VEGF) in the development of retinopathy, and multidisciplinary management strategies focusing on ocular as well as systemic risk factor interventions that can help individualize care and promote healthy vision in diabetes.

TARGET AUDIENCE

This activity is designed to meet the educational needs of primary care providers, ophthalmologists, and other healthcare providers who manage patients who have or are at risk for DR/DME.

LEARNING OBJECTIVES

After completing the CME activity, learners should be better able to:

• Implement evidence-based recommendations for diabetic retinopathy (DR) screening and monitoring
• Investigate available technologies that can help increase screening rates and detection of retinopathy
• Identify the role of VEGF in the development of diabetes-related retinopathy
• Examine the importance of early identification and timely treatment of DR and/or DME
• Cultivate a team-based approach in caring for the DR patient
• Summarize the systemic and ocular treatments that are effective in the treatment of patients with diabetic eye disease

ACCREDITATION STATEMENT: Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT: Med Learning Group designates this virtually live activity for a maximum of 1.0 AMA PRA Category 1 credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NURSES (ANCC) CREDIT DESIGNATION

Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at [email protected].

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]